[Form 4] Zimmer Biomet Holdings, Inc. Insider Trading Activity
Rhea-AI Filing Summary
Lori Winkler, Senior Vice President and CHRO of Zimmer Biomet Holdings, reported sales of common stock on September 8, 2025. The Form 4 discloses 1,500 shares sold at a weighted average price of $104.15 per share (individual sale prices ranged from $104.15 to $104.18). After the transactions, Ms. Winkler beneficially owns 6,833 shares, held directly. The sale was reported on the Form 4 filed September 10, 2025, and was executed by an attorney-in-fact on her behalf.
Positive
- None.
Negative
- None.
Insights
Routine insider sale; small size relative to typical executive holdings, likely neutral.
The Form 4 shows a direct sale of 1,500 shares by the company CHRO at a weighted average price of $104.15, reducing direct beneficial ownership to 6,833 shares. The filing includes an explanatory note that the sale occurred in multiple transactions on September 8, 2025, and affirms availability of detailed pricing per lot upon request. There is no indication in the filing of any plan-based transaction (no 10b5-1 box checked), no amendment to prior filings, and no derivative activity reported. As presented, this appears to be a routine disposition rather than a material corporate event.
Disclosure complies with Section 16 timing; no governance red flags apparent from this filing alone.
The Form 4 is signed by an attorney-in-fact and contains the required explanatory footnote about weighted average pricing across multiple lots. Reporting identifies the filer as an officer (SVP and CHRO) and indicates direct ownership form. The report does not reference plans or exemptions that would change the interpretation of the sale. From a governance and compliance perspective, the filing meets disclosure requirements and does not reveal related-party transactions or other governance concerns within the document.